輝瑞公司 |
Pfizer |

????2012年《財(cái)富》500強(qiáng)排名:第48位 ????2012年利潤(單位:百萬美元):14,570 ????2011年11月,作為輝瑞公司的頭號(hào)暢銷藥之一,,立普妥的專利保護(hù)到期,,導(dǎo)致公司當(dāng)年第四季度利潤損失慘重(同期公司基本醫(yī)療藥物營收也下滑8%)。為此,,輝瑞公司下調(diào)了2012年業(yè)績(jī)預(yù)期,。盡管如此,這個(gè)藥業(yè)巨頭2012年的業(yè)績(jī)依然靚麗:截至年底,,公司年利潤高達(dá)145.7億美元,,較2011年的100億美元增長了45.6%。這也意味著輝瑞在《財(cái)富》500強(qiáng)盈利榜單上的排名從2011年的第17位勁升至2012年的第11位,。這個(gè)成績(jī)對(duì)于輝瑞來說實(shí)屬不易,,因?yàn)樗鼉赡臧胫霸馐芰斯芾韺又亟M的重大打擊,當(dāng)時(shí)該公司的這一重大調(diào)整備受外界關(guān)注,。 ????——Daniel Roberts |
????Fortune 500 rank: 48 ????2012 profit (millions): 14,570 ????One of the biggest crown jewels in Pfizer's drug portfolio, Lipitor, came off patent in November 2011, resulting in a big profit loss in Q4 of that year (revenue for its primary care medicines also went down 8% in that period). Pfizer, as a result, lowered its 2012 outlook. Despite that, the pharma giant had a banner year: by the end of 2012 it was in fact up 45.6% in profits, with $14.57 billion vs. a mere $10 billion in 2011. That also means it has leapfrogged from No. 17 most profitable in the Fortune500 last year to No. 11. Not bad for a corporation that only two and a half years ago suffered a damaging and much-scrutinized management shakeup. -- Daniel Roberts |